SAS-B approvals hit all-time high in April as Tasmania spikes again by Steve Jones May 2, 2025May 2, 2025 A record number of Special Access Scheme medicinal cannabis prescriptions were approved by the Therapeutic Goods […]
News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire by Steve Jones and Martin Lane April 23, 2025April 23, 2025
SAS-B approvals hit second highest on record as Tassie shows surprise growth by Steve Jones April 2, 2025April 2, 2025
Althea blames medical sales decline on TGA ‘falling asleep at the wheel’ amid ‘crazy’ antics of competitors by Steve Jones March 21, 2025March 26, 2025
Two-month total of SAS-B approvals up 47% on 2024, TGA data shows by Steve Jones March 4, 2025April 1, 2025
Pastilles drive Bioxyne to first-half profit after revenue climbs 171% by Steve Jones March 3, 2025March 3, 2025
Growth of pastilles accelerates as SAS approvals get off to strong start in 2025 by Steve Jones February 17, 2025February 17, 2025
Bioxyne sees sharp revenue growth as shares jump after strong quarter by Steve Jones October 17, 2024February 25, 2025
Pastilles gaining in popularity as SAS-B approvals maintain strong start to 2024 by Steve Jones May 6, 2024July 16, 2024
